Regeneron Highlights Hematology Pipeline Progress at ASH 2024
Key Insights
Regeneron will present head-to-head data of pozelimab plus cemdisiran versus ravulizumab in paroxysmal nocturnal hemoglobinuria (search) (PNH) at the ASH 2024 meeting.
Initial results for odronextamab in first-line follicular lymphoma (search) (FL) will be showcased, highlighting its potential as a monotherapy in the OLYMPIA-1 trial.
Additional presentations will explore odronextamab in diffuse large B-cell lymphoma (search) (DLBCL) progressing after CAR-T therapy and relapsed/refractory marginal zone lymphoma (search) (MZL).
Regeneron Pharmaceuticals will present new and updated data from its hematology pipeline across 23 abstracts at the American Society of Hematology (ASH) 2024 Annual Meeting, from December 7-10 in San Diego, CA. The data will highlight progress in addressing unmet needs across ten types of blood cancers and disorders using diverse modalities, including bispecific antibodies and siRNA combinations.
Novel Combination Therapy for Paroxysmal Nocturnal Hemoglobinuria
An oral presentation will feature head-to-head results from an exploratory cohort of a Phase 3 trial evaluating the combination of pozelimab and cemdisiran compared to ravulizumab in patients with paroxysmal nocturnal hemoglobinuria (search) (PNH) who were complement inhibition-naïve at baseline. The presentation will detail interim results from patients who crossed over from ravulizumab to the combination therapy in an open-label extension.
Odronextamab in Follicular Lymphoma and Other B-Cell Lymphomas
Twelve abstracts will feature progress on the odronextamab development program. Initial results from Part 1 of the Phase 3 OLYMPIA-1 confirmatory trial in previously untreated follicular lymphoma (search) (FL) will be presented. This part of the trial consists of a non-randomized safety run-in, followed by a randomized efficacy portion (Part 2) comparing odronextamab monotherapy to rituximab plus standard-of-care chemotherapies.
Two oral presentations will cover new analyses from the ELM-1 and pivotal ELM-2 trials in settings with significant unmet needs. One presentation will focus on patients with diffuse large B-cell lymphoma (search) (DLBCL) who progressed after CAR-T therapy, and the other will present first results in relapsed/refractory (R/R) marginal zone lymphoma (search) (MZL).
Linvoseltamab in Multiple Myeloma
Additional notable abstracts include the latest efficacy and safety results for linvoseltamab from the pivotal LINKER-MM1 study in R/R multiple myeloma (search) (MM). Preclinical data evaluating a CD38xCD28 costimulatory bispecific antibody in combination with linvoseltamab, and preclinical data on TMPRSS6 (search) inhibition in beta-thalassemia (search) will also be presented.
Regeneron's Commitment
L. Andres Sirulnik, M.D., Ph.D., Senior Vice President and Hematology Clinical Development Unit Head at Regeneron, stated, "Our presentations at ASH demonstrate the progress we are making toward transforming care for a range of blood cancers and disorders where advancements are desperately needed. These include new head-to-head data exploring a novel combination that aims to maximize disease control in paroxysmal nocturnal hemoglobinuria (search) compared to a standard-of-care treatment, as well as initial results from our confirmatory odronextamab trial in first-line follicular lymphoma (search). Together, our presentations underscore our commitment to work towards translating scientific breakthroughs to differentiated medicines for hematology patients."